1-甲氧基-4-氟萘 | 10471-09-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-甲氧基-4-氟萘
• 英文名称: 1-methoxy-4-fluoronaphthalene
• 英文别名: 4-fluoro-1-methoxynaphthalene；4-fluoro-1-methoxy-naphthalene；1-Fluor-4-methoxynaphthalin；1-Fluoro-4-methoxynaphthalene
• CAS: 10471-09-7
• 化学式: C₁₁H₉FO
• 分子量: 176.19
• InChiKey: STHIPSLAOJKIPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-甲氧基-4-氟萘 在 cesium fluoroxysulphate 、 三氟化硼 作用下， 以 乙腈 为溶剂， 反应 0.5h， 以77%的产率得到2,4-difluoro-1-methoxynaphthalene
  参考文献：
  名称：

  Fluorination with cesium fluoroxysulfate. Room temperature fluorination of benzene and naphthalene derivatives

  摘要：

  DOI：

  10.1021/jo00219a032
• 作为产物：
  描述：

  4-氟-1-萘醛 在 氢氧化钾 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 丁酮 为溶剂， 反应 12.25h， 生成 1-甲氧基-4-氟萘
  参考文献：
  名称：

  A Convenient Large-Scale Synthesis of 4-Fluoro-1-naphthaldehyde and Its Aromatic Nucleophilic Substitution Reactions

  摘要：

  DOI：

  10.1021/jo00125a055

文献信息

• Selective and Efficient Direct Fluorination of Polycyclic Aromatic Hydrocarbons Using 1-Fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane Bis(tetrafluoroborate)
  作者：Stojan Stavber、Marko Zupan

  DOI：10.1246/cl.1996.1077

  日期：1996.12

  bis(tetrafluoroborate) (AccufluorTM NFTh) was effectively used for selective fluorination of polycyclic aromatics. Naphthalene was site-selectively fluorinated to 1-fluoronaphthalene, phenanthrene to 9-fluorophenanthrene, and pyrene to 1-fluoropyrene. In a series of substituted naphthalenes the regioselectivity and effectiveness of fluorination depended on the position and the nature of the substituents.

  一种新的NF氟化试剂1-氟-4-羟基-1,4-重氮二环[2.2.2]辛烷双（四氟硼酸盐）（AccufluorTM NFTh）有效地用于多环芳烃的选择性氟化。萘经位点选择性氟化为 1-氟萘，菲为 9-氟菲，芘为 1-氟芘。在一系列取代的萘中，氟化的区域选择性和有效性取决于取代基的位置和性质。
• Lewis Acid Catalyzed Highly Selective Halogenation of Aromatic Compounds
  作者：Hisashi Yamamoto、Yanhua Zhang、Kazutaka Shibatomi

  DOI：10.1055/s-2005-918919

  日期：——

  A simple and efficient procedure for the halogenation of aromatic compounds with NCS, NBS, NIS and NFSI in the presence of catalytic amount of ZrCl4 is described. Chlorination, bromination, iodination and fluorination of various aromatic compounds are performed with high selectivity under mild reaction conditions.

  描述了一种简单高效的芳香化合物卤化程序，该过程使用NCS、NBS、NIS和NFSI，并在催化量ZrCl4的存在下进行。各种芳香化合物的氯化、溴化、碘化和氟化在温和反应条件下具有很高的选择性。
• INHIBITORS OF CXCR2
  申请人：HACHTEL Stephanie

  公开号：US20090215827A1

  公开（公告）日：2009-08-27

  The invention relates to compounds of the formula I in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

  该发明涉及公式I的化合物，其中R1，R2，X，A，B和Y1到Y4具有所述权利要求中指示的含义，和/或其药学上可接受的盐和/或前药。由于它们作为趋化因子受体抑制剂的特性，特别是作为CXCR2抑制剂，公式I的化合物和其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。
• CXCR2 INHIBITORS
  申请人：HACHTEL Stephanie

  公开号：US20090227625A1

  公开（公告）日：2009-09-10

  The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

  本发明涉及公式I的化合物，其中R1、R2、X、A、B、Z和Y1到Y4具有所述权利要求中指示的含义，和/或其药学上可接受的盐和/或前药。由于它们作为趋化因子受体抑制剂的特性，尤其是作为CXCR2抑制剂，公式I的化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。
• CXCR2 inhibitors
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US08283479B2

  公开（公告）日：2012-10-09

  The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

  本发明涉及I式化合物，其中R1、R2、X、A、B、D和Y1到Y4具有所述权利要求中指定的含义，以及/或其药学上可接受的盐和/或前药。由于它们作为趋化因子受体抑制剂的特性，特别是作为CXCR2抑制剂，I式化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。